NOS2 and neoplasm: This network is not only central to tumor initiation and progression but also provides a wealth of translational targets, from RNS-specific diagnostic probes (e.g., BODIPY for NO, near-infrared probes for ONOO−) to therapeutic agents (e.g., the iNOS inhibitors 1400W and AG, the GST-activated NO prodrug JS-K).